迪哲医药(688192) - 2022 Q3 - 季度财报

Financial Performance - The net profit attributable to shareholders for the third quarter was -165,196,869.25 RMB, with a year-to-date total of -510,097,218.65 RMB[2] - The basic earnings per share for the third quarter was -0.41 RMB, and the diluted earnings per share was also -0.41 RMB[4] - The weighted average return on net assets for the third quarter was -8.07%, compared to -23.03% for the same period last year[4] - Net profit for Q3 2022 was a loss of ¥510,097,218.65, compared to a loss of ¥466,389,270.28 in Q3 2021, indicating a worsening of approximately 9.4%[18] - The company reported a basic and diluted earnings per share of -¥1.26 for Q3 2022, slightly improved from -¥1.30 in Q3 2021[19] Revenue and Expenses - The company has not yet commenced commercial production or sales for any of its research products, resulting in no revenue from sales[8] - Total revenue for the first three quarters of 2022 reached ¥6,619,152.00, compared to ¥5,800,609.08 in the same period of 2021[17] - Operating costs for the first three quarters of 2022 were ¥547,752,560.05, an increase from ¥475,720,288.67 in 2021, reflecting a year-over-year growth of approximately 15.1%[17] - Research and development expenses for the third quarter amounted to 151,076,338.85 RMB, representing a 1.02% increase compared to the same period last year[4] - Research and development expenses for the first three quarters of 2022 totaled ¥480,663,642.45, up from ¥407,288,810.30 in 2021, representing an increase of about 17.9%[17] - Management expenses increased by 33.23% year-to-date due to company expansion and increased personnel[8] Cash Flow - The net cash flow from operating activities for the third quarter was -141,087,822.00 RMB, with a year-to-date total of -421,450,780.29 RMB[4] - The company's cash flow from operating activities showed a significant decline, contributing to the overall net loss reported[18] - In the first three quarters of 2022, the cash inflow from operating activities totaled ¥77,623,965.11, a significant increase from ¥26,128,637.69 in the same period of 2021[20] - The cash outflow from operating activities reached ¥499,074,745.40, compared to ¥364,574,934.34 in the previous year, resulting in a net cash flow from operating activities of -¥421,450,780.29[20] Assets and Liabilities - Total assets at the end of the reporting period were 2,267,628,907.88 RMB, a decrease of 17.41% from the previous year[4] - The company's total current assets decreased from RMB 2,112,337,442.79 at the end of 2021 to RMB 1,644,289,196.26 as of September 30, 2022, representing a decline of approximately 22.2%[14] - The company's total liabilities as of Q3 2022 amounted to ¥300,403,755.22, compared to ¥282,911,205.38 in the previous year, marking an increase of approximately 6.4%[16] - The total equity attributable to shareholders decreased to ¥1,967,225,152.66 in Q3 2022 from ¥2,462,845,979.46 in Q3 2021, a decline of about 20.1%[16] Investments and Subsidies - The company reported a significant increase of 2013.03% in investment income year-to-date, primarily from holding IPO fundraising[8] - The company received government subsidies amounting to 1,800,000.00 RMB during the third quarter, with a total of 3,919,137.00 RMB year-to-date[5] - The cash inflow from investment activities was ¥6,755,055,010.28, a substantial rise from ¥397,659,754.50 year-over-year[21] - The cash outflow from investment activities amounted to ¥6,547,990,011.83, compared to ¥308,129,534.36 in the same period last year, leading to a net cash flow from investment activities of ¥207,064,998.45[21] - The company reported a significant increase in cash received from investment income, totaling ¥29,863,735.94, compared to ¥1,659,754.50 in the previous year[21] Shareholder Information - The total number of common shareholders at the end of the reporting period was 18,377, with the largest shareholder holding 26.95% of shares[9] - The company’s largest shareholder, ZYTZ and its concerted action party, Wuxi Dize, collectively hold 15.49% of the shares[11] Product Development - The company's leading product, DZD9008, achieved a confirmed clinical trial objective with a cORR of 59.8% for patients with EGFR Exon 20 insertion mutation advanced non-small cell lung cancer[12] - The company received a drug production license from the Jiangsu Provincial Drug Administration, ensuring qualifications for future product commercialization[12]